Zealand Pharma Ownership
Who are the major shareholders and have insiders been buying or selling?
Recent Insider Transactions
Date | Value | Name | Entity | Role | Shares | Max Price |
---|---|---|---|---|---|---|
21 Dec 24 | BuyDKK 236,460 | Leonard Kruimer | Individual | 331 | DKK 720.00 | |
08 Nov 24 | SellDKK 1,273,500 | Anneline Nansen | Individual | 1,500 | DKK 850.00 | |
29 Aug 24 | SellDKK 30,730,000 | Adam Steensberg | Individual | 35,000 | DKK 878.00 |
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Owner Type | Number of Shares | Ownership Percentage |
---|---|---|
Individual Insiders | 195,382 | 0.276% |
VC/PE Firms | 6,874,960 | 9.72% |
General Public | 25,639,781 | 36.3% |
Institutions | 37,983,860 | 53.7% |
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Ownership | Name | Shares | Current Value | Change % | Portfolio % | |
---|---|---|---|---|---|---|
6,874,960 | DKK 2.9b | 0% | 56.87% | |||
4,400,863 | DKK 1.8b | 102% | 0.01% | |||
3,438,184 | DKK 1.4b | 0% | 3.55% | |||
3,138,798 | DKK 1.3b | 0% | 0.68% | |||
3,095,511 | DKK 1.3b | 0% | 2.95% | |||
2,659,939 | DKK 1.1b | 1.36% | no data | |||
2,275,861 | DKK 949.3m | 0.01% | 0.01% | |||
2,105,067 | DKK 878.0m | 0.75% | no data | |||
1,835,158 | DKK 765.4m | 0% | 0.01% | |||
1,537,304 | DKK 641.2m | -0.35% | 0.04% | |||
1,351,448 | DKK 563.7m | 0% | 0.11% | |||
1,335,128 | DKK 556.9m | 0.58% | 0.02% | |||
951,127 | DKK 396.7m | 2.35% | 0.95% | |||
894,738 | DKK 373.2m | 0% | 0.02% | |||
706,437 | DKK 294.7m | 0% | 0.03% | |||
594,894 | DKK 248.1m | 0% | 0.02% | |||
543,908 | DKK 226.9m | -17.8% | no data | |||
517,754 | DKK 216.0m | 0.18% | no data | |||
492,739 | DKK 205.5m | -2.24% | 0.02% | |||
483,867 | DKK 201.8m | -26.2% | 0.07% | |||
432,220 | DKK 180.3m | 0.46% | no data | |||
414,776 | DKK 173.0m | 4,740% | 0.01% | |||
406,192 | DKK 169.4m | 41% | no data | |||
344,893 | DKK 143.9m | -1.01% | 0.15% | |||
319,000 | DKK 133.1m | -20.7% | 0.16% |
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/05/16 01:58 |
End of Day Share Price | 2025/05/16 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zealand Pharma A/S is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Laura Hindley | Berenberg |
Kerry Holford | Berenberg |
Charlie Haywood | BofA Global Research |